Lung Cancer

PD 16 - Lung 4 - Poster Discussion

1138 - Impact of Intensity Modulated Radiation Therapy on Acute Toxicity in Locally Advanced Lung Cancer: Results of a Large Statewide Multi-center Cohort

Wednesday, October 24
11:18 AM - 11:24 AM
Location: Room 217 C/D

Impact of Intensity Modulated Radiation Therapy on Acute Toxicity in Locally Advanced Lung Cancer: Results of a Large Statewide Multi-center Cohort
S. Jolly1, M. Schipper2, Y. Sun2, P. A. Paximadis3, L. L. Kestin4, I. S. Grills5, B. Movsas6, T. P. Boike7, M. Wilson4, M. M. Matuszak8, L. J. Pierce1, and J. A. Hayman1; 1Michigan Medicine, Ann Arbor, MI, 2Department of Biostatistics, University of Michigan, Ann Arbor, MI, 3Lakeland Radiation Oncology, St. Joseph, MI, 4Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, MI, 5Beaumont Health, Royal Oak, MI, 6Henry Ford Health System, Detroit, MI, 7McLaren Northern Michigan, Petoskey, MI, 8Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

Purpose/Objective(s): Secondary analysis of RTOG 0617 has shown lower rates of pneumonitis and less decline in patient quality of life with the use of intensity modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) in locally advanced non-small cell lung cancer patients undergoing definitive radiation therapy. In a large statewide radiation oncology quality consortium, we sought to evaluate impact of IMRT vs. 3D-CRT treatment technique on acute esophagitis and pneumonitis. Materials/Methods: From 2013 to 2017, 1919 patients with non-metastatic lung cancer were enrolled in the consortium. Physician reported toxicity by CTCAE and patient reported outcomes using FACT Lung Cancer Subscale (LCS) and FACT Trials Outcome Index (TOI) were collected at 1, 3 and 6 months from the end of radiation. We compared physician and patient reported quality of life by treatment technique. Normal tissue dose volume constraints and PTV objectives were not prospectively controlled. To account for differences in prognostic factors between IMRT and 3D-CRT patients, we performed inverse probability of treatment weighting (IPTW) via a propensity score. The propensity score was estimated via a logistic regression model and included age, smoking status, comorbidities, stage, PTV volume, chemotherapy, prescription dose, total number of structures and individual structures (e.g. esophagus, heart) within 2cm of the PTV. Results: 1237 non-surgical locally advanced lung cancer patients met inclusion criteria. After excluding patients with missing variables, 1062 (86%) were included in the analysis. 31% were treated with 3D-CRT and 69% were treated with IMRT. Compared with 3D-CRT patients, IMRT patients had significantly larger PTVs (mean 370 vs 474cc) and were more likely to be stage IIIB (24% vs 32%). In logistic regression models using IPTW, there were no significant differences between 3D-CRT and IMRT in rates of esophagitis (Odds Ratio =0.95; 95% CI=0.70, 1.32; p=0.76) or pneumonitis (OR = 0.91; 95% CI:0.43, 1.92; p=0.80). At 6 months after completion of RT with a compliance of 45%, 3D-CRT and IMRT resulted in similar proportions of patient experiencing a decline of at least 2 points on LCS (38% vs 45%, p=0.33) and at least 5 points on TOI (48% vs 54%, p=0.72). Conclusion: In these data from a statewide consortium of academic and community radiation oncology practices, despite the PTV being larger among patients treated with IMRT vs 3D-CRT, no significant difference in acute esophagitis or pneumonitis by radiation treatment technique was found. Further analysis is underway seeking to use patient variables and dose relationships to identify a subgroup of patients in which IMRT may reduce toxicity relative to 3D-CRT.
Author Disclosure: S. Jolly: None. M. Schipper: None. Y. Sun: None. P.A. Paximadis: None. L.L. Kestin: board member; Michigan Healthcare Professionals. National Director of Thoracic & Lung Care Services; 21st Century Oncology. I.S. Grills: Board of Directors; Greater Michigan Gamma Knife. B. Movsas: Research Grant; Varian Medical Systems, Inc, Philips, Inc, NCI. Travel Expenses; Varian Medical Systems, Inc, Philips, Inc. Patent/License Fees/Copyright; Henry Ford Health System. Chair, Quality of Life Subcommittee; Radiation Therapy Oncology Group/NRG. T.P. Boike: Partner; Petoskey Radiation Oncology. Honoraria; ASTRO APEx Reviewer. Member; NCI Prostate Cancer Task Force. M. Wilson: None. M.M. Matuszak: Employee; William Beaumont Hospital. L.J. Pierce: Royalty; UpToDate. J.A. Hayman: Research Grant; Blue Cross Blue Shield of Michigan.

Shruti Jolly, MD

Disclosure:
Employment
University of Michigan: Associate Professor: Employee, Faculty: Employee

Biography:
Shruti Jolly MD is an Associate Professor and Associate Chair of Community Practices in the Department of Radiation Oncology at the University of Michigan. She received her undergraduate and medical degrees at Wayne State University as a Presidential Scholar. In 2007, she completed her medical training at William Beaumont Hospital in Royal Oak, Michigan where she served as chief resident and received the RSNA Roentgen Resident Research Award. Dr. Jolly then joined the faculty at the University of Michigan Department of Radiation Oncology. Dr. Jolly directs the treatment of thoracic, gynecologic and endocrine malignancies. She also serves as the director of Brachytherapy, specializing in High Dose Rate (HDR) brachytherapy procedures. Additionally, she is the principal investigator of numerous clinical protocols designed to individualize the radiation therapy of lung and gynecologic cancer patients. Dr. Jolly has authored numerous publications in peer-reviewed journals. As Associate chair of Community Practices, she oversees the standardization and quality of care of patients receiving radiation therapy at the numerous UM Radiation Oncology community practices across the state of Michigan. In addition, she serves as a consultant for the Michigan Radiation Oncology Quality Consortium (MROQC) focused on quality improvement in patients undergoing radiation therapy for breast cancer, lung cancer and bone metastases.

Presentation(s):

Send Email for Shruti Jolly


Assets

1138 - Impact of Intensity Modulated Radiation Therapy on Acute Toxicity in Locally Advanced Lung Cancer: Results of a Large Statewide Multi-center Cohort



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Impact of Intensity Modulated Radiation Therapy on Acute Toxicity in Locally Advanced Lung Cancer: Results of a Large Statewide Multi-center Cohort